CJC-1295 with Ipamorelin — The Growth Hormone Stack That Works Better Together

There is an elegant piece of biology at the heart of why CJC-1295 and Ipamorelin are almost always used together rather than alone. The pituitary gland — the small structure at the base of the brain responsible for releasing growth hormone — has two separate receptor systems that both govern GH release. Activate one and you get a response. Activate both simultaneously and you get something fundamentally different — a GH pulse that is not just doubled but amplified to three to five times baseline. That synergistic effect is the entire rationale for this stack, and it is grounded in well-established receptor pharmacology rather than speculation.

Researchers studying growth hormone release discovered something counterintuitive early on — triggering a single receptor, either the GHRH receptor or the ghrelin receptor, produces a modest, short-lived GH pulse. Activating both simultaneously creates a response up to ten times larger than either alone. Amazon

CJC-1295 activates the GHRH receptor. Ipamorelin activates the ghrelin receptor. Together they create the most widely used growth hormone peptide stack in the research community — and as of 2026, one of the fastest growing areas of peptide interest with search volume climbing from 27,000 searches per month in late 2025 to over 60,000 per month in 2026. Amazon

This page covers both compounds in full — what each one is, how they work together, the DAC versus no-DAC question that confuses many people new to this stack, the complete dosing and reconstitution protocol, and honest expectations about what this combination can and cannot achieve.

What Are CJC-1295 and Ipamorelin?

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone — GHRH — the hormone the hypothalamus naturally produces to signal the pituitary gland to release growth hormone. It is a 30-amino-acid peptide that binds GHRH receptors on pituitary somatotrophs — the cells that produce and release GH. Think of it as the production-side signal — telling the pituitary to make GH and prepare to release it. ALM Corp

CJC-1295 is available in two forms — with DAC and without DAC. DAC stands for Drug Affinity Complex — a modification that allows the peptide to bind to albumin in the bloodstream, dramatically extending its half-life from 30 minutes to 2 hours without DAC to 6 to 8 days with DAC. This changes the dosing frequency completely — CJC-1295 without DAC is dosed daily, while CJC-1295 with DAC is dosed once or twice weekly.

Ipamorelin is a 5-amino-acid pentapeptide — one of the smallest and most selective growth hormone secretagogues available. It binds the ghrelin receptor — GHSR1a — on the same pituitary cells that CJC-1295 targets, triggering GH release through a completely separate pathway. Ipamorelin’s high selectivity for GHSR1a means it stimulates GH release without the cortisol and prolactin elevations seen with GHRP-6 and GHRP-2, and without the pronounced appetite stimulation that GHRP-6 produces via off-target ghrelin receptor activity in the gut. For combination stacks in recovery and body composition research, Ipamorelin’s cleaner side effect profile makes it the preferred choice. Amazon

Together they represent a complete two-signal approach to natural growth hormone stimulation — one peptide on each receptor system, both targeting the same pituitary cells, both working toward the same outcome through completely different biological pathways.

How Does the Stack Work?

CJC-1295 Ipamorelin peptide therapy is not hormone replacement. It does not replace your growth hormone. It signals your pituitary gland to produce and release your own growth hormone in a pattern that more closely resembles what your body produced in your twenties. Amazon

This distinction matters enormously — both for understanding what the stack does and for appreciating why it has a significantly cleaner profile than direct growth hormone administration. The pituitary retains control of the release process. The feedback systems that prevent excessive GH production remain intact. The result is a natural pulsatile GH pattern, amplified in magnitude, rather than the constant supraphysiological levels associated with direct HGH use.

Combined CJC-1295 without DAC plus Ipamorelin produces GH pulse amplitudes averaging 3 to 5 times baseline in preclinical models, compared to roughly 1.5 to 2 times with either compound used alone. That is not a marginal difference. Amazon

The downstream effects of this amplified GH pulse flow through IGF-1 — Insulin-like Growth Factor 1 — produced primarily in the liver in response to GH stimulation. IGF-1 is responsible for the tissue-level effects of growth hormone — cellular repair, muscle protein synthesis, fat metabolism, collagen production, bone density maintenance and the broad spectrum of recovery and body composition changes that make this stack one of the most versatile in the library.

The timing advantage of the pre-sleep protocol is particularly important to understand. A 2025 study in Growth Hormone and IGF Research found that administration during the early sleep phase produced approximately 40% greater IGF-1 elevation compared to daytime dosing, consistent with the natural GH secretion peak that occurs during slow-wave sleep. This is why pre-sleep administration is the standard protocol — not convention but biology, aligning the peptide-driven GH pulse with the body’s own largest natural daily GH release. The Peptide Effect

CJC-1295 With DAC or Without DAC?

This is the question that causes most confusion for people new to this stack and it deserves a direct and clear answer.

CJC-1295 without DAC is the preferred choice for use with Ipamorelin because its 30-minute to 2-hour half-life matches Ipamorelin’s roughly 2-hour half-life — preserving the body’s natural pulsatile GH release. CJC-1295 with DAC has a 6 to 8 day half-life and a different planning model that fits poorly with Ipamorelin’s short pulse. ALM Corp

In practical terms — CJC-1295 without DAC and Ipamorelin are taken together in the same injection once daily before sleep. They have matching half-lives, produce a clean synchronised GH pulse together, and are often supplied as a pre-blended combined vial for exactly this reason.

CJC-1295 with DAC is used differently — dosed once or twice weekly on its own schedule, producing a sustained rather than pulsatile GH elevation. Some people use it in combination with Ipamorelin on separate schedules but this is a more complex approach that most people new to growth hormone peptides do not need to start with.

For the majority of people reading this page the recommendation is straightforward — CJC-1295 without DAC combined with Ipamorelin, once daily before sleep.

What Does the Research Show?

The evidence base for CJC-1295 and Ipamorelin individually and in combination includes both human and animal studies across a range of goals.

For CJC-1295 specifically the foundational human data comes from the Walker et al. 2006 study published in the Journal of Clinical Endocrinology and Metabolism. Healthy adults receiving CJC-1295 with DAC at 30 or 60 mcg per kg subcutaneously showed mean GH AUC increases of 200 to 400% over 6 days post-injection. Those are significant and well documented effects on growth hormone elevation in humans. Amazon

Ipamorelin’s evidence base includes the foundational Raun et al. 1998 study that characterised its selectivity and GH releasing profile — establishing it as the cleanest growth hormone secretagogue available in terms of side effect profile.

The CJC-1295 Ipamorelin stack benefits a specific set of goals — visceral fat reduction, faster muscle recovery and deeper sleep — by triggering the pituitary gland to release more growth hormone rather than replacing it. Used together these two peptides produce a stronger more sustained GH pulse than either does alone. Audible

The practical outcomes most consistently reported across both research settings and real world use include improved sleep quality — typically within the first two to four weeks — followed by enhanced recovery from training, progressive improvements in body composition, and the broader spectrum of effects associated with optimised growth hormone levels including improved skin quality, joint health and energy. 

Who Is This Stack Most Relevant For?

The CJC-1295 with Ipamorelin stack has one of the broadest relevant audiences of any compound in this library — which is part of why it has become the most widely used growth hormone peptide combination available.

Athletes and active people aged 25 to 45 who train consistently and want to optimise recovery, body composition and training performance will find this one of the most directly relevant stacks in the library. The combination of amplified GH pulse, improved sleep quality and enhanced tissue repair creates a compound effect that serious trainers find genuinely meaningful.

People over 40 experiencing the natural age-related decline in growth hormone production — which typically reduces by around 14% per decade after the age of 25 — find this stack particularly relevant for reversing some of the body composition changes, recovery deterioration and sleep quality decline associated with that decline.

Anyone using other peptide protocols — including the weight loss compounds covered earlier in this section — will find CJC-1295 with Ipamorelin a coherent addition for lean tissue preservation during caloric restriction, which is one of its most consistently cited applications.

Dosage and Protocol

Standard Research Protocol — CJC-1295 without DAC with Ipamorelin:

• CJC-1295 without DAC: 100 to 200mcg per injection
• Ipamorelin: 100 to 200mcg per injection
• Administration: Both compounds injected together as a single subcutaneous injection — they can be drawn into the same insulin syringe immediately before use and do not chemically interact
• Timing: Once daily before sleep — on an empty stomach, at least 2 hours after the last meal. The fasted pre-sleep window is critical — food-driven insulin elevation blunts the GH pulse
• Frequency: Once daily — five days on two days off is a common cycling approach to prevent receptor desensitisation, though some protocols use daily administration throughout
• Cycle length: 12 to 16 weeks, followed by a break of 4 to 8 weeks before repeating

For those who prefer the CJC-1295 with DAC option:

• CJC-1295 with DAC: 1 to 2mg once or twice weekly — on its own schedule, separate from Ipamorelin
• Ipamorelin: 100 to 200mcg once daily before sleep as above
• This approach is more complex and better suited to those with prior experience of growth hormone peptide protocols

Standard dosing is 100 to 200mcg of each compound administered together as a single subcutaneous injection before sleep. Expected timeline — improved sleep quality in weeks 1 to 4, improved recovery and energy in weeks 4 to 8, modest body composition changes possible at weeks 8 to 16 with appropriate training. GREY Journal

Reconstitution & Mixing Guide

CJC-1295 with Ipamorelin is commonly available as a pre-blended combined vial — typically containing 10mg or 20mg total (5mg or 10mg of each compound). It is also available as separate individual vials.

Using a pre-blended 10mg vial (5mg CJC-1295 + 5mg Ipamorelin) as the reference:

Add 2ml of bacteriostatic water:

• Total concentration = 5,000mcg per ml (2,500mcg of each per ml)
• Each unit on a 100-unit insulin syringe = 25mcg of each compound
• A 100mcg dose of each = 4 units
• A 200mcg dose of each = 8 units

Add 1ml of bacteriostatic water:

• Total concentration = 10,000mcg per ml (5,000mcg of each per ml)
• Each unit on a 100-unit insulin syringe = 50mcg of each compound
• A 100mcg dose of each = 2 units
• A 200mcg dose of each = 4 units

Add 3ml of bacteriostatic water:

• Total concentration = 3,333mcg per ml (1,667mcg of each per ml)
• Each unit on a 100-unit insulin syringe = 16.67mcg of each compound
• A 100mcg dose of each = 6 units
• A 200mcg dose of each = 12 units

For most people adding 2ml to a 10mg blend vial creates the most practical working concentration — the numbers are straightforward and the injection volume is comfortable.

If using separate vials — reconstitute each individually using the same principles above, then draw the required volume of each into the same insulin syringe immediately before injection. They do not chemically interact and can be safely combined in the syringe.

On a U-100 syringe, 6 units equals 0.06ml equals 200mcg of each peptide from a 20mg blend at 3.0ml — a useful reference point for those using the larger vial size. ALM Corp

Reconstitution Method

Inject bacteriostatic water slowly down the inside wall of the vial — never directly onto the powder. Gently swirl rather than shake until fully dissolved. The solution should be clear and colourless.

Storage

Reconstituted solution — refrigerate at 2 to 8 degrees Celsius, use within 28 to 30 days. Do not freeze. Lyophilised powder — refrigerate away from light and moisture until reconstituted.

Supporting Supplements

The supplements that best support CJC-1295 with Ipamorelin are those that complement growth hormone activity, support the tissue repair and body composition changes the stack drives, and maintain the sleep quality in which the protocol operates most effectively.

Zinc and Magnesium — both directly relevant to growth hormone production and release. Zinc is involved in GH synthesis and IGF-1 activity. Magnesium supports the deep sleep in which the most significant GH pulse occurs and in which the stack’s effects are most pronounced. Taking both before sleep alongside the peptide administration is a coherent and well-reasoned approach.

Vitamin D maintains the hormonal and metabolic environment in which growth hormone activity produces the most meaningful results — its relationship with IGF-1 signalling makes it particularly relevant.

Collagen peptides — specifically Type 1 and Type 3 — taken with Vitamin C before sleep has been shown to support connective tissue repair in the context of elevated GH activity. For anyone using this stack specifically for joint health or injury recovery this combination is particularly relevant.

Creatine monohydrate — for those using the stack in a training and body composition context. The combination of amplified GH pulse and creatine’s well-established effects on muscle energy systems and protein synthesis creates a genuinely synergistic training support approach.

Protein — adequate daily protein intake is essential for the muscle protein synthesis that elevated IGF-1 activity drives. Without sufficient protein the anabolic signal has nothing to work with. 1.6 to 2g per kilogram of bodyweight daily is the well-evidenced target for active people using this stack for body composition goals.

Foods That Complement CJC-1295 with Ipamorelin

The most important nutritional consideration for this stack is the pre-sleep fasted window — maintaining a clean fast of at least 2 hours before the pre-sleep injection is essential. Insulin elevation from a recent meal directly blunts the GH pulse that CJC-1295 and Ipamorelin are working to produce.

Through the rest of the day the nutritional approach that best supports the stack centres on adequate protein at every meal — lean meats, fish, eggs, dairy, legumes — to provide the amino acid building blocks that elevated IGF-1 activity will use for tissue synthesis and repair.

Complex carbohydrates timed around training support the energy demands of consistent resistance training — which is the lifestyle factor that makes this stack most effective. Post-workout nutrition with protein and carbohydrates supports the recovery window that the pre-sleep GH pulse will then build upon overnight.

Oily fish — salmon, mackerel, sardines — delivers omega-3 fatty acids that support both the anti-inflammatory environment in which tissue repair occurs and the cardiovascular health that intensive training demands.

Avoiding late night eating is particularly important during a CJC-1295 with Ipamorelin protocol — the pre-sleep injection window requires a clean fasted state, and the habit of eating late works directly against one of the most important practical requirements of the stack.

Lifestyle Considerations

Resistance training is the lifestyle factor that unlocks the most meaningful body composition results from this stack. The amplified GH and IGF-1 activity the combination drives translates most powerfully into lean tissue development when the muscles are being given a progressive training stimulus to respond to. Without consistent resistance training the body composition effects are significantly more modest. With it — particularly in the 8 to 16 week range of a full cycle — the combination of amplified recovery, improved sleep quality and elevated IGF-1 is genuinely meaningful.

Sleep quality is not just beneficial alongside this stack — it is the operating environment in which the stack’s most significant effects occur. Administration during the early sleep phase produced approximately 40% greater IGF-1 elevation compared to daytime dosing. Protecting sleep duration and quality is one of the highest leverage actions available to anyone running this protocol. The Peptide Effect

The pre-sleep fasted window — at least 2 hours after the last meal before injection — is non-negotiable for getting meaningful GH pulse amplification. This is the single most commonly missed practical detail in growth hormone peptide protocols and one of the most important.

Stress management — chronic cortisol elevation directly antagonises growth hormone release and IGF-1 activity. The HPA axis overactivation that chronic stress produces is one of the most significant barriers to getting meaningful results from this stack.

Peptide Pairing

CJC-1295 with Ipamorelin appears on pairing recommendations throughout this library — it is one of the most versatile and frequently combined compounds available.

BPC-157 is a particularly coherent daytime pairing for anyone using the stack for recovery and injury — BPC-157 driving tissue repair and angiogenesis during waking hours while CJC-1295 with Ipamorelin amplifies the overnight repair and regeneration phase. Many active people running recovery protocols use this combination as their core stack.

TB-500 similarly complements the overnight recovery amplification of this stack with its own systemic tissue repair and actin regulation effects — used during the day while CJC-1295 with Ipamorelin works overnight.

AOD-9604 pairs naturally for body composition goals — AOD-9604 targeting fat metabolism during the day through beta-3 adrenergic pathways while CJC-1295 with Ipamorelin drives growth hormone mediated body composition improvement overnight.

Epithalon in a longevity-focused protocol — addressing telomere biology and pineal function alongside the growth hormone axis optimisation of this stack creates a genuinely comprehensive approach to healthy ageing.

Realistic Expectations

CJC-1295 with Ipamorelin is one of the best evidenced and most consistently well-tolerated growth hormone peptide stacks available — and the timeline of its effects is one of the most predictable in the library.

Improved sleep quality is typically the first and most consistently reported effect — usually noticeable within weeks 1 to 4. Improved recovery, energy and training performance follow in weeks 4 to 8. Meaningful body composition changes — reduced body fat, improved lean tissue — become apparent from weeks 8 to 16 with consistent training. GREY Journal

It is not a dramatic or rapid body transformation compound. It works gradually and cumulatively — producing effects that build meaningfully over a 12 to 16 week cycle and that are most significant in people who are already training consistently and eating well. For those people — particularly athletes and active individuals in their late 20s through to their 50s who are experiencing the effects of age-related GH decline — it is one of the most genuinely valuable compounds in the library.

The absence of the cortisol and prolactin elevations seen with GHRP-6, the clean side effect profile of Ipamorelin, and the well-documented synergistic mechanism make it a stack that can be used consistently across multiple cycles with a confidence that few other growth hormone approaches can match.